Nearly 80 million Americans — one out of every four people — are infected with human papillomavirus (HPV). And of those millions, more than 31,000 will be diagnosed with an HPV-related cancer this year. Despite those staggering figures and the availability of a vaccine to prevent the infections that cause these cancers, HPV vaccination remains low in the United States.
Often what kills cancer patients is not the cancer at its original or primary site, but its spread to secondary sites within the body, through a process called metastasis. In the case of breast cancer, the tumor often spreads to the bone, and it is this bone metastasis that results in intense pain and precedes spread to other organs.
Huntsman Cancer Institute announced today that it has been certified to offer both chimeric antigen receptor (CAR) T cell therapies recently approved by the U.S. Food and Drug Administration. The therapies are approved for types of aggressive blood cancers, including B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. HCI is one of a few locations nationwide, and the only in the Mountain West, approved to offer these new therapies to adult cancer patients.
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) today announced the opening of the Cancer Population Sciences and Huntsman Center for Health Outcomes and Population Equity (HOPE), a new research and clinical space dedicated to preventing cancer and improving health among underserved populations and improving outcomes in cancer patients. The center recently received $9.7 million from the Patient-Centered Outcomes Research Institute (PCORI) to fund a clinical trial researching new and effective approaches to reduce tobacco use.
Gliomas are the most common type of central nervous system cancer but how these tumors develop is not fully understood. Sheri Holmen, PhD a researcher at Huntsman Cancer Institute (HCI) and professor of surgery at the University of Utah just published the results of her research on gliomas in Cell Reports. The work is focused on a mutated gene that is a critical piece of the puzzle for glioma development, according to Holmen’s work.
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.
New research from Huntsman Cancer Institute (HCI) at the University of Utah (U of U) indicates steroid and hormone receptors are simultaneously active in many endometrial cancer tissues. The findings, published today in the journal Cell Reports, yield insights about factors that contribute to more aggressive endometrial tumors.
The Board of Directors of Huntsman Cancer Foundation has elected Peter R. Huntsman as Chairman of the Board effective immediately. He replaces his father, Jon M. Huntsman, Sr., who founded Huntsman Cancer Institute (HCI) and was its principal benefactor. Jon M. Huntsman passed away earlier this month.
New research from Huntsman Cancer Institute (HCI) at the University of Utah (U of U) illuminates aspects of how an early embryo, the product of fertilization of a female egg cell by a male sperm cell, can give rise to all the many cell types of the adult animal. The findings, published today in the journal Cell, have significant implications for understanding how early development is orchestrated, and provides a mechanism for how parental environment might impact the expression of these genes in the offspring.
We are truly saddened at the passing of our remarkable founder and benefactor, Jon M. Huntsman, this afternoon. He passed away peacefully at home, surrounded by his loving family. Other than his family, his greatest passion was to eradicate cancer. We will honor his legacy by continuing to provide hope and healing to all impacted by this disease.
Researchers have identified two gene regions that contribute to multiple myeloma, an inherited cancer that occurs in bone marrow, through a new method that makes use of human disease pedigrees. Nicola Camp and Rosalie Waller of Huntsman Cancer Institute at the University of Utah and colleagues report their findings February 1st in PLOS Genetics.
Huntsman Cancer Institute (HCI) at the University of Utah has been awarded a $2.4 million, two-year grant from the National Cancer Institute (NCI) to help continue its research in breast cancer. Alana Welm, PhD and Bryan Welm, PhD, investigators at HCI, along with Michael Lewis, PhD, a colleague at Baylor College of Medicine, will use this new funding to serve as a Breast Cancer Patient-derived xenograft Development and Trials Center (PDTC) to research and test new drugs for breast cancer. This new Center is only one of four such Centers in the nation.
Researchers developed a new mathematical tool to validate and improve methods used by medical professionals to interpret results from clinical genetic tests. The work was published this month in Genetics in Medicine.
The research was led by Sean Tavtigian, PhD, a cancer researcher at Huntsman Cancer Institute (HCI) and professor of oncological sciences at the University of Utah, in collaboration with genetics experts from around the United States.
Mary Beckerle, PhD, CEO and Director of Huntsman Cancer Institute (HCI) at the University of Utah, is this year’s recipient of the Alfred G. Knudson Award in Cancer Genetics from the National Cancer Institute (NCI).
A new study by researchers at Huntsman Cancer Institute (HCI) at the University of Utah observed how breast cancer tumors evolve over time and demonstrated how changes within tumors may contribute to the process by which cancers no longer respond to treatment. Further, the research identifies that some of these changes may be shared across certain treatment-resistant breast cancers. The study was published this month in Nature Communications.
Risk for aging-related diseases such as heart disease and diabetes was significantly higher among thyroid cancer survivors in Utah than it was among age-matched, cancer-free individuals, with those diagnosed before age 40 having the highest risk for some of the diseases, according to results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research
People with an inherited syndrome called familial adenomatous polyposis (FAP) have a 100% lifetime risk of developing colorectal cancer if they do not seek appropriate medical care. Recent findings published by researchers at Huntsman Cancer Institute at the University of Utah identified a promising prevention treatment for patients with FAP.
The results of a national cancer survey find a significant number of childhood cancer survivors are worried about keeping their health insurance, to the point of letting it affect their career decisions. The findings were published today in JAMA Oncology. Anne Kirchhoff, PhD, investigator at Huntsman Cancer Institute (HCI) at the University of Utah and assistant professor of pediatrics, led the study. Her goal was to examine the prevalence of job lock in full-time, employed childhood cancer survivors. Job lock is when an employee stays at a job in order to keep work-related health insurance.
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah and collaborators at University of Utah Health (U of U Health) sheds light on the complex process that occurs in the development of human sperm stem cells. This is the first study to characterize the changes human sperm stem cells undergo as they mature. The results have implications for understanding male infertility as well as cancer development and were published today in the journal Cell Stem Cell.
Huntsman Cancer Institute (HCI) at the University of Utah has announced David Gaffney, MD, PhD, as Senior Director for Clinical Research. In this position, Gaffney oversees HCI’s clinical research efforts which include more than 200 active clinical cancer trials at any given time.